James Rolke - Revelation Biosciences CEO Director
| REVBW Stock | USD 0.01 0.0004 3.33% |
Insider
James Rolke is CEO Director of Revelation Biosciences
| Age | 55 |
| Address | 4660 La Jolla Village Drive, San Diego, CA, United States, 92122 |
| Phone | 650 800 3717 |
| Web | https://www.revbiosciences.com |
James Rolke Latest Insider Activity
Tracking and analyzing the buying and selling activities of James Rolke against Revelation Biosciences stock is an integral part of due diligence when investing in Revelation Biosciences. James Rolke insider activity provides valuable insight into whether Revelation Biosciences is net buyers or sellers over its current business cycle. Note, Revelation Biosciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Revelation Biosciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
James Rolke over a year ago Acquisition by James Rolke of 2542 shares of Revelation Biosciences subject to Rule 16b-3 |
Revelation Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.5098) % which means that it has lost $0.5098 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (2.7002) %, meaning that it generated substantial loss on money invested by shareholders. Revelation Biosciences' management efficiency ratios could be used to measure how well Revelation Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.01 in 2024. Return On Capital Employed is likely to climb to -1.24 in 2024. At this time, Revelation Biosciences' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to climb to about 198.9 K in 2024, whereas Non Current Assets Total are likely to drop slightly above 61.8 K in 2024.Similar Executives
| Found 7 records | INSIDER Age | ||
| Susan Prohaska | Jasper Therapeutics | N/A | |
| William Lis | Jasper Therapeutics | 60 | |
| Chester III | Revelation Biosciences | 44 | |
| Carol Zoltowski | Jasper Therapeutics | 74 | |
| Carol Odle | Revelation Biosciences | N/A | |
| Kevin MD | Jasper Therapeutics | 53 | |
| Jeet MBA | Jasper Therapeutics | N/A | |
Management Performance
| Return On Equity | -2.7 | ||||
| Return On Asset | -0.51 |
Revelation Biosciences Leadership Team
Elected by the shareholders, the Revelation Biosciences' board of directors comprises two types of representatives: Revelation Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Revelation. The board's role is to monitor Revelation Biosciences' management team and ensure that shareholders' interests are well served. Revelation Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Revelation Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| James Rolke, CEO Director | ||
| Carol Odle, Director Projects | ||
| Chester III, Chief Officer | ||
| Sandra Vedrick, Vice Relations |
Revelation Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Revelation Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.7 | ||||
| Return On Asset | -0.51 | ||||
| Number Of Shares Shorted | 17.31 K | ||||
| EBITDA | (95.21 K) | ||||
| Net Income | (120.25 K) | ||||
| Cash And Equivalents | 4.14 M | ||||
| Cash Per Share | 1.79 X | ||||
| Total Debt | 5.56 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 2.58 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Revelation Stock Analysis
When running Revelation Biosciences' price analysis, check to measure Revelation Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Revelation Biosciences is operating at the current time. Most of Revelation Biosciences' value examination focuses on studying past and present price action to predict the probability of Revelation Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Revelation Biosciences' price. Additionally, you may evaluate how the addition of Revelation Biosciences to your portfolios can decrease your overall portfolio volatility.